<DOC>
	<DOCNO>NCT00539162</DOCNO>
	<brief_summary>The goal clinical research study evaluate method involve blood test , call CA-125 , may helpful early detection ovarian cancer woman low risk .</brief_summary>
	<brief_title>Use CA 125 Algorithm Early Detection Ovarian Cancer Low Risk Women</brief_title>
	<detailed_description>Currently , effective screening detect ovarian cancer early stage low risk woman . CA-125 FDA approve blood test may show presence ovarian cancer . If eligible take part research study : - You blood ( 2-3 tablespoon ) draw CA-125 test tumor marker . Tumor marker may relate presence certain cancer . - You ask complete questionnaire medical family history . It take 20-30 minute complete . - You ask complete questionnaire symptom . It take 10-15 minute complete . Depending CA-125 level : - You blood ( 2-3 tablespoon ) draw CA-125 test tumor marker 1 year . - You blood ( 2-3 tablespoon ) draw CA-125 test tumor marker 3 month , OR - You blood ( 2-3 tablespoon ) draw CA-125 test tumor marker , transvaginal ultrasound ( look ovary fallopian tube ) 6 week +/- 2 month . An ultrasound test use sound wave check position , size , shape ovary . During transvaginal ultrasound , small probe place vagina use create measure sound wave . Based result transvaginal ultrasound ( receive one ) : - You study doctor discus option treatment standard cancer management , OR - You blood ( 2-3 tablespoon ) draw CA-125 test tumor marker 3 month . When return next visit ( 1 year , 3 month , 6 week +/- 2 week ) , visit : - You blood ( 2-3 tablespoon ) draw CA-125 test tumor marker . - You ask complete questionnaire symptom . - You ask complete follow-up visit survey update personal family medical history record . It take 10 minute complete . Your CA-125 blood draw result send letter e-mail know return visit . If miss visit , study staff may try contact telephone , e-mail , letter . Visit reminder may also send letter e-mail . Length Study : You continue return visit depend CA-125 level last visit . If unable return visit 3 year , take study . You may continue take part study unless long qualify study longer would like take part study . This investigational study . Transvaginal ultrasound scan study perform use FDA-approved commercially available method . Up 8,000 woman take part multicenter study . Up 2,000 enrol MD Anderson .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>1 . Female , &gt; /= 50 year old less 75 year old . 2 . Postmenopausal ( &gt; /= 12 month amenorrhea ) . 3 . Have least one ovary . 4 . Cancerfree receive chemotherapy radiation therapy &gt; /=12 month prior enrol study . 5 . Willingness return CA 125 blood test annually earlier indicate . 6 . Willingness return undergo transvaginal ultrasound indicate . 7 . Women need provide name gynecologist qualify healthcare professional willing provide appropriate followup care indicate 1 . Female : Less 50 year old old 75 year time enrollment . 2 . Psychiatric psychological condition prevent fully inform consent . 3 . Prior removal ovary . 4 . Active nonovarian malignancy . 5 . Women history nonovarian malignancy eligible persistent recurrent disease receive treatment &gt; 12 month . If SERMS ( i.e . tamoxifen aromatase inhibitor ) exclude . Women maybe undergo treatment &lt; 12 month prior study entry basal cell carcinoma . 6 . High risk ovarian cancer due familial predisposition define follow : . Known mutation BRCA1 BRCA2 . b . Two 1st 2nd degree relative lineage : two ovarian cancer ; one ovarian cancer &amp; one premenopausal breast cancer ; two premenopausal breast cancer ; one premenopausal &amp; one postmenopausal breast cancer . ( These condition also meet use patient one 1st 2nd degree female relative . ) c. Ashkenazi Jewish descent one 1st degree two 2nd degree relative premenopausal breast ovarian cancer participant premenopausal breast cancer . d. 1st 2nd degree male relative breast cancer diagnose age . ( First degree relative define child , sibling parent . Second degree relative define halfsiblings , aunt , uncle , niece , nephew , grandparent , grandchild . ) 7 . Hereditary Nonpolyposis Colorectal Cancer ( HNPCC ) /Lynch Syndrome : know genetic mutation , presume HNPCC carrier , Amsterdam criterion .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>CA 125 Algorithm</keyword>
	<keyword>Cancer Detection</keyword>
	<keyword>Questionnaire</keyword>
	<keyword>Survey</keyword>
</DOC>